Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacogenetic Testing in Early-Phase Psychosis
NCT02566057Completed
- Sponsor
- Northwell Health
- Start
- Jul 2014
- Primary completion
- Dec 2017
- Countries
- 1
01
Overview
Randomised, single-blind trial in schizophrenia, schizoaffective disorder, schizophreniform disorder and 2 more (2 arms), sponsored by Northwell Health. Primary endpoint: Time to Discontinuation of First Medication at 12 months. Started Jul 2014; status: completed.
02
Conditions
schizophreniaschizoaffective disorderschizophreniform disorderpsychotic disorderbipolar disorder (BD)
Beyond the preview
Go deeper on NCT02566057.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02566057.